Tonghua

Tonghua sells more processed biology than border romance. In the first 11 months of 2024, the city's ginseng industry produced ¥37.8 billion ($5.2 billion) of output and spawned more than 800 products across over 450 businesses. Set 375 metres above sea level in Jilin, Tonghua has roughly 510,000 residents in its urban core and is usually described as a forested prefecture city near Changbai Mountain. The deeper story is that Tonghua has spent decades turning mountain ecology into a pharmaceutical and wellness manufacturing system.

Jilin's own industrial policy says the city will anchor a modern pharmaceutical and health cluster worth more than ¥151 billion by 2025, and Tonghua Pharmaceutical High-Tech Industrial Development Zone won national high-tech zone status in 2023. Those are not random subsidies. Tonghua sits in a region with 66.6% forest coverage and long familiarity with ginseng, herbs, and cold-climate processing. Instead of shipping raw plants and timber out like a simple resource town, it keeps moving up the chain: extracts, capsules, tonics, branded foods, and research platforms all stack on top of the same biological base. That is why Tonghua matters. It is one of Northeast China's cleaner examples of a place refusing commodity status by converting local ecology into repeatable industrial formats.

Mycelium is the right organism. A fungal network does not depend on one mushroom; it spreads through a substrate and keeps sending up new fruiting bodies wherever nutrients allow. Tonghua does the same with forest medicine. Path dependence fits because the city's current industrial logic was built on earlier herb and pharmaceutical specialization. Adaptive radiation fits because one ginseng base now supports hundreds of products and business types. Resource allocation fits because provincial and national policy keep channeling capital into the part of the city that can multiply raw biology into industrial output.